Cipla Limited CIPLA.NS Stock
Cipla Limited Price Chart
Cipla Limited CIPLA.NS Financial and Trading Overview
Cipla Limited stock price | 1399.55 INR |
Previous Close | 998.2 INR |
Open | 1000 INR |
Bid | 1004.2 INR x 0 |
Ask | 1004.05 INR x 0 |
Day's Range | 993.75 - 1004.75 INR |
52 Week Range | 852 - 1185.25 INR |
Volume | 878.23K INR |
Avg. Volume | 2.15M INR |
Market Cap | 810.82B INR |
Beta (5Y Monthly) | 0.273287 |
PE Ratio (TTM) | 28.988455 |
EPS (TTM) | 45.95 INR |
Forward Dividend & Yield | 8.5 (0.86%) |
Ex-Dividend Date | July 20, 2023 |
1y Target Est | 1060.63 INR |
CIPLA.NS Valuation Measures
Enterprise Value | 754.5B INR |
Trailing P/E | 28.988455 |
Forward P/E | 20.113136 |
PEG Ratio (5 yr expected) | 1.24 |
Price/Sales (ttm) | 3.5635386 |
Price/Book (mrq) | 3.463561 |
Enterprise Value/Revenue | 3.316 |
Enterprise Value/EBITDA | 15.009 |
Trading Information
Cipla Limited Stock Price History
Beta (5Y Monthly) | 0.273287 |
52-Week Change | 9.12% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1185.25 INR |
52 Week Low | 852 INR |
50-Day Moving Average | 934.23 INR |
200-Day Moving Average | 1019.46 INR |
CIPLA.NS Share Statistics
Avg. Volume (3 month) | 2.15M INR |
Avg. Daily Volume (10-Days) | 1.55M INR |
Shares Outstanding | 807.22M |
Float | 533.86M |
Short Ratio | N/A |
% Held by Insiders | 35.36% |
% Held by Institutions | 33.86% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 8.5 |
Trailing Annual Dividend Yield | 0.85% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.1441 |
Last Split Factor | 5:2 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 12.31% |
Operating Margin (ttm) | 16.94% |
Gross Margin | 63.73% |
EBITDA Margin | 22.09% |
Management Effectiveness
Return on Assets (ttm) | 8.51% |
Return on Equity (ttm) | 12.63% |
Income Statement
Revenue (ttm) | 227.53B INR |
Revenue Per Share (ttm) | 281.95 INR |
Quarterly Revenue Growth (yoy) | 10.29% |
Gross Profit (ttm) | 145.01B INR |
EBITDA | 50.27B INR |
Net Income Avi to Common (ttm) | 28.02B INR |
Diluted EPS (ttm) | 34.65 |
Quarterly Earnings Growth (yoy) | 45.20% |
Balance Sheet
Total Cash (mrq) | 46.54B INR |
Total Cash Per Share (mrq) | 57.67 INR |
Total Debt (mrq) | 8.03B INR |
Total Debt/Equity (mrq) | 3.39 INR |
Current Ratio (mrq) | 3.381 |
Book Value Per Share (mrq) | 290.005 |
Cash Flow Statement
Operating Cash Flow (ttm) | 32.38B INR |
Levered Free Cash Flow (ttm) | -532350016 INR |
Profile of Cipla Limited
Country | India |
State | N/A |
City | Mumbai |
Address | Cipla House |
ZIP | 400013 |
Phone | 91 22 2482 6000 |
Website | https://www.cipla.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
Q&A For Cipla Limited Stock
What is a current CIPLA.NS stock price?
Cipla Limited CIPLA.NS stock price today per share is 1399.55 INR.
How to purchase Cipla Limited stock?
You can buy CIPLA.NS shares on the NSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cipla Limited?
The stock symbol or ticker of Cipla Limited is CIPLA.NS.
Which industry does the Cipla Limited company belong to?
The Cipla Limited industry is Drug Manufacturers-General.
How many shares does Cipla Limited have in circulation?
The max supply of Cipla Limited shares is 807.37M.
What is Cipla Limited Price to Earnings Ratio (PE Ratio)?
Cipla Limited PE Ratio is 30.45810700 now.
What was Cipla Limited earnings per share over the trailing 12 months (TTM)?
Cipla Limited EPS is 45.95 INR over the trailing 12 months.
Which sector does the Cipla Limited company belong to?
The Cipla Limited sector is Healthcare.
Cipla Limited CIPLA.NS included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NIFTY 50 NSEI | 22315.6 INR 269.98 USD |
-0.91
|
— — | 22302.5 INR 269.82 USD | 22373.55 INR 270.68 USD | — - | — — |
Nasdaq EM Plus Korea Large Cap NQEMKRLCGBPN | 1820.04 GBP 2327.71 USD |
<0.01
|
— — | 1820.04 GBP 2327.71 USD | 1820.04 GBP 2327.71 USD | — - | — — |
- {{ link.label }} {{link}}